Literature DB >> 28040471

Developmental effects of imatinib mesylate on follicle assembly and early activation of primordial follicle pool in postnatal rat ovary.

Babak Asadi-Azarbaijani1, Regiane R Santos2, Kirsi Jahnukainen3, Saskia Braber4, Majorie B M van Duursen4, Jorma Toppari5, Ola D Saugstad6, Mirja Nurmio5, Irma C Oskam7.   

Abstract

Imatinib mesylate is an anti-cancer agent that competitively inhibits several receptor tyrosine kinases (RTKs). RTKs play important roles in the regulation of primordial follicle formation, the recruitment of primordial follicles into the pool of growing follicles and maturation of the follicles. In the present study, we investigated the effects of the tyrosine kinase inhibitor imatinib on primordial follicle assembly and early folliculogenesis in postnatal rats. Female Sprague-Dawley rats were treated with either imatinib (150mg/kg) or placebo (water) on postnatal days 2-4. Bilateral ovariectomy was performed on postnatal day 2 and 5. Histology, immunohistochemistry, and mRNA analysis were performed. Imatinib treatment was associated with increased density of the multi-oocyte follicles (P<0.01), oogonia (p<0.01) and germline clusters (P<0.05), decreased activation of primordial follicles, increased expression of c-Kit and AMH, and decreased protein expression of Kit-ligand and GDF9 when compared to age-matched controls. In conclusion, imatinib affects folliculogenesis in postnatal rat ovaries by delaying the cluster breakdown, follicular assembly and early activation of the primordial follicle pool.
Copyright © 2016 Society for Biology of Reproduction & the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Folliculogenesis; Imatinib; Oogenesis; Ovary; Rat

Mesh:

Substances:

Year:  2016        PMID: 28040471     DOI: 10.1016/j.repbio.2016.11.003

Source DB:  PubMed          Journal:  Reprod Biol        ISSN: 1642-431X            Impact factor:   2.376


  7 in total

Review 1.  Can Some Anticancer Treatments Preserve the Ovarian Reserve?

Authors:  Nicolas Vallet; Nicolas Boissel; Elisabeth Elefant; Florian Chevillon; Hélène Pasquer; Charlotte Calvo; Nathalie Dhedin; Catherine Poirot
Journal:  Oncologist       Date:  2021-01-29

2.  Regulation of mouse primordial follicle formation by signaling through the PI3K pathway†.

Authors:  Joshua J N Burton; Amanda J Luke; Melissa E Pepling
Journal:  Biol Reprod       Date:  2022-03-19       Impact factor: 4.285

3.  Primordial Follicle Formation - Some Assembly Required.

Authors:  Jessica M O'Connell; Melissa E Pepling
Journal:  Curr Opin Endocr Metab Res       Date:  2021-03-20

4.  Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro.

Authors:  Qiuyue Liao; Xue Feng; Xi Li; Ge Chen; Jing Chen; Bin Yang; Kezhen Li; Jihui Ai
Journal:  Oncol Rep       Date:  2020-06-24       Impact factor: 3.906

5.  Acylated Ghrelin Supports the Ovarian Transcriptome and Follicles in the Mouse: Implications for Fertility.

Authors:  Luba Sominsky; Jeferson F Goularte; Zane B Andrews; Sarah J Spencer
Journal:  Front Endocrinol (Lausanne)       Date:  2019-01-15       Impact factor: 5.555

6.  Control of growth and development of preantral follicle: insights from in vitro culture.

Authors:  José Ricardo de Figueiredo; Laritza Ferreira de Lima; José Roberto Viana Silva; Regiane Rodrigues Santos
Journal:  Anim Reprod       Date:  2018-08-03       Impact factor: 1.810

7.  Equol: A Microbiota Metabolite Able to Alleviate the Negative Effects of Zearalenone during In Vitro Culture of Ovine Preantral Follicles.

Authors:  Talyne Emilia Santos Silva; Danielle Cristina Calado de Brito; Naiza Arcângelo Ribeiro de Sá; Renato Felix da Silva; Anna Clara Accioly Ferreira; José Ytalo Gomes da Silva; Maria Izabel Florindo Guedes; Ana Paula Ribeiro Rodrigues; Regiane Rodrigues Dos Santos; José Ricardo de Figueiredo
Journal:  Toxins (Basel)       Date:  2019-11-09       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.